Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

Published:2019-01-30 Issue:1 Volume:33 Page:15-32
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

T. Virtanen Anniina,Haikarainen Teemu,Raivola Juuli,Silvennoinen Olli

Funder

Academy of Finland

Sigrid Juséliuksen Säätiö

Division of Cancer Epidemiology and Genetics, National Cancer Institute

Jane ja Aatos Erkon Säätiö

Tampereen Tuberkuloosisäätiö

Pirkanmaa hospital district competitive research funding

Novo Nordisk Fonden

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/article/10.1007/s40259-019-00333-w/fulltext.html

Reference159 articles.

1. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.

2. Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst. 2006;2:536–50.

3. Delgoffe GM, Vignali DAA. STAT heterodimers in immunity. Jak-Stat. 2013;2:e23060.

4. Hammarén HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2018. https://doi.org/10.1016/j.cyto.2018.03.041 (Epub 2018 May 21).

5. Ferrao R, Lupardus PJ. The Janus kinase (JAK) FERM and SH2 domains: bringing specificity to JAK-receptor interactions. Front Endocrinol (Lausanne). 2017;8:71.

Cited by 214 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship;Bioorganic Chemistry;2024-11

2. Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116;Pharmaceutics;2024-08-31

3. Ozanimod (Zeposia) An S1P Receptor Modulator for Treating Multiple Sclerosis and Inflammatory Bowel Diseases;Chemistry and Pharmacology of Drug Discovery;2024-08-16

4. Tazemetostat (Tazverik) An EZH2 Inhibitor for Treatment of Epithelioid Sarcoma and Follicular Lymphoma;Chemistry and Pharmacology of Drug Discovery;2024-08-16

5. Odevixibat (Bylvay) A Selective Inhibitor of the Ileal Bile Acid Transporter;Chemistry and Pharmacology of Drug Discovery;2024-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3